This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Epelman, S. Articles by Sen, S. Search for Related Content PubMed Articles by Epelman, S. Articles by Sen, S. Related Collections Related Articles

CLINICAL RESEARCH: HEART FAILURE

Detection of Soluble Angiotensin-Converting Enzyme 2 in Heart Failure

Insights Into the Endogenous Counter-Regulatory Pathway of the Renin-Angiotensin-Aldosterone System

Slava Epelman, MD, PhD^_*, W.H. Wilson Tang, MD, FACC^,, Stephen Y. Chen, MD^_*, Frederick Van Lente, PhD, Gary S. Francis, MD, FACC and Subha Sen, PhD, DSc^,_*

^_* Department of Internal Medicine, Heart and Vascular Institute, Cleveland, Ohio
Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland, Ohio
Department of Cell Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio
Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.

Manuscript received December 3, 2007; revised manuscript received February 7, 2008, accepted February 26, 2008.

^_* Reprint requests and correspondence: Dr. Subha Sen, Department of Molecular Cardiology, NB50, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195. (Email: sens{at}ccf.org).

Objectives: We sought to determine whether circulating soluble angiotensin-converting enzyme 2 (sACE2) is increased in the plasma of patients with heart failure (HF).

Background: Angiotensin-converting enzyme 2 (ACE2) is an integral membrane protein that antagonizes the actions of angiotensin II and prevents the development of HF in animal models. However, because of the need for invasive cardiac tissue sampling, little is known about whether ACE2 is involved in the pathophysiology of HF in humans.

Methods: We developed a sensitive and specific assay to measure sACE2 activity in human plasma and screened a heterogeneous group of patients suspected of having clinical HF.

Results: Increasing sACE2 plasma activity strongly correlated with a clinical diagnosis of HF (p = 0.0002), worsening left ventricular ejection fraction (p < 0.0001), and increasing B-type natriuretic peptide levels (p < 0.0001). Similar to B-type natriuretic peptide, sACE2 activity reflected the severity of HF, with increasing levels associated with worsening New York Heart Association functional class (p < 0.0001). These associations were independent of other disease states and medication use. We found that sACE2 activity was increased in patients with both ischemic and nonischemic cardiomyopathies and also in patients with clinical HF but a preserved left ventricular ejection fraction.

Conclusions: Soluble ACE2 activity is increased in patients with HF and correlates with disease severity, suggesting that a cardioprotective arm of the renin-angiotensin-aldosterone system is active in HF.

Key Words: heart failure • ACE2 • hypertrophy • soluble

Abbreviations and Acronyms   ACE2 = angiotensin-converting enzyme 2   Ang = angiotensin   BNP = B-type natriuretic peptide   HF = heart failure   NYHA = New York Heart Association   RAAS = renin-angiotensin-aldosterone system   sACE2 = soluble angiotensin-converting enzyme 2

Related Articles

An ACE in the Hole: Alternative Pathways of the Renin Angiotensin System and Their Potential Role in Cardiac Remodeling

Barry Greenberg
J. Am. Coll. Cardiol. 2008 52: 755-757. [Full Text] [PDF]

This article has been cited by other articles:

				M. Iwata, J. E. Silva Enciso, and B. H. Greenberg Selective and specific regulation of ectodomain shedding of angiotensin-converting enzyme 2 by tumor necrosis factor {alpha}-converting enzyme Am J Physiol Cell Physiol, November 1, 2009; 297(5): C1318 - C1329. [Abstract] [Full Text] [PDF]

				Z. Kassiri, J. Zhong, D. Guo, R. Basu, X. Wang, P. P. Liu, J. W. Scholey, J. M. Penninger, and G. Y. Oudit Loss of Angiotensin-Converting Enzyme 2 Accelerates Maladaptive Left Ventricular Remodeling in Response to Myocardial Infarction Circ Heart Fail, September 1, 2009; 2(5): 446 - 455. [Abstract] [Full Text] [PDF]

				G. Boerrigter, L. C. Costello-Boerrigter, G. J. Harty, B. K. Huntley, A. Cataliotti, H. Lapp, and J. C. Burnett Jr. B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2009; 296(6): R1744 - R1750. [Abstract] [Full Text] [PDF]

				J. McMurray, M. Petrie, K. Swedberg, M. Komajda, S. Anker, and R. Gardner CHAPTER 23 Heart Failure ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]

				B. Greenberg An ACE in the Hole: Alternative Pathways of the Renin Angiotensin System and Their Potential Role in Cardiac Remodeling J. Am. Coll. Cardiol., August 26, 2008; 52(9): 755 - 757. [Full Text] [PDF]